Skip to main content
Legit Tirzepatide

An independent reading of the tirzepatide evidence — what is actually approved, what the cardiometabolic trials measured, and how to tell the real record from the noise.

About Legit Tirzepatide | Tirzepatide

What this site is

Legit Tirzepatide is a reading room for the peer-reviewed tirzepatide record — the large, rigorous trial literature read carefully and set out in order. No clinic operates behind the reading room; no one here treats patients, prescribes, or gives medical advice. It makes nothing, sells nothing, and ships nothing. Its work is to read the published evidence clearly and cite it exactly, keeping the noise that surrounds this compound out of the room.

The domain name carries the intent. A great deal of what circulates about tirzepatide online is noise — promotional framing dressed as information, compounded-product sourcing dressed as education, and speculation dressed as trial data. The legitimate evidence record is large, rigorous, and accessible. This site's job is to read it clearly and cite it exactly.

Editorial method

Every quantitative claim on this site traces to a published citation. Inline reference markers [N] link to the full citation list on the Tirzepatide references page. We do not write claims that are not in the cited literature. We do not invent citations.

The compound class is FDA-approved, which means the clinical evidence base includes randomised controlled trials at a scale rarely seen in pharmacology: tens of thousands of participants across the SURPASS, SURMOUNT, SUMMIT, SURMOUNT-OSA, and SYNERGY-NASH programmes, plus a dedicated cardiovascular outcomes trial (SURPASS-CVOT). Our summaries draw from that literature directly.

Evidence gaps are noted as gaps. Where findings are preliminary, observational, or statistically uncertain, those qualifications appear in the text. The goal is accurate characterisation of the evidence — not advocacy for or against the compound.

What this site is not

Legit Tirzepatide does not offer medical advice. It does not recommend any course of treatment. It does not provide dosing recommendations beyond what is documented in the FDA prescribing information and cited clinical trial protocols.

The 'legit' in the domain name is editorial framing — a position this publisher occupies relative to the evidence, not a claim about healthcare services. There are no clinicians, pharmacists, nurses, or healthcare staff behind this site. There is no physical address or phone number.

If you are considering tirzepatide for any indication, that decision should involve a licensed prescriber who knows your medical history. This site is a reading room for the published science, not a substitute for clinical care.

Contact

Questions, corrections, or citation issues can be sent via the contact page. We take citation accuracy seriously — if you have found a factual error, misattribution, or a broken reference link, we want to know.